Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 101 | 2023 | 6934 | 7.590 |
Why?
|
HIV Infections | 113 | 2023 | 16678 | 4.720 |
Why?
|
Viral Load | 37 | 2022 | 3292 | 3.340 |
Why?
|
Botswana | 57 | 2023 | 1040 | 2.870 |
Why?
|
RNA, Viral | 24 | 2019 | 2899 | 2.550 |
Why?
|
HIV Seropositivity | 14 | 2023 | 970 | 2.550 |
Why?
|
Anti-HIV Agents | 26 | 2023 | 4250 | 2.040 |
Why?
|
Drug Resistance, Viral | 18 | 2023 | 820 | 1.730 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 6 | 2018 | 222 | 1.690 |
Why?
|
Phylogeny | 33 | 2023 | 2797 | 1.560 |
Why?
|
Proviruses | 5 | 2020 | 316 | 1.340 |
Why?
|
DNA, Viral | 11 | 2019 | 2224 | 1.190 |
Why?
|
Epidemics | 5 | 2022 | 521 | 1.100 |
Why?
|
Anti-Retroviral Agents | 12 | 2023 | 1712 | 1.050 |
Why?
|
HIV Antigens | 6 | 2018 | 347 | 1.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 13 | 2020 | 1872 | 0.990 |
Why?
|
Cluster Analysis | 8 | 2022 | 2713 | 0.950 |
Why?
|
Reverse Transcriptase Inhibitors | 6 | 2022 | 615 | 0.930 |
Why?
|
Genotype | 21 | 2023 | 12946 | 0.820 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 213 | 0.790 |
Why?
|
HIV Envelope Protein gp120 | 8 | 2014 | 952 | 0.790 |
Why?
|
HIV Antibodies | 8 | 2018 | 1320 | 0.760 |
Why?
|
Molecular Epidemiology | 7 | 2022 | 468 | 0.680 |
Why?
|
Serologic Tests | 2 | 2018 | 374 | 0.650 |
Why?
|
CD4 Lymphocyte Count | 14 | 2020 | 2557 | 0.640 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.610 |
Why?
|
Evolution, Molecular | 8 | 2016 | 1937 | 0.550 |
Why?
|
Antibody Affinity | 1 | 2016 | 253 | 0.540 |
Why?
|
AIDS Vaccines | 7 | 2006 | 938 | 0.500 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2016 | 602 | 0.490 |
Why?
|
Genetic Variation | 15 | 2022 | 6540 | 0.480 |
Why?
|
Kenya | 4 | 2023 | 685 | 0.460 |
Why?
|
Sampling Studies | 1 | 2014 | 623 | 0.450 |
Why?
|
Mutation | 18 | 2023 | 29717 | 0.440 |
Why?
|
Nevirapine | 8 | 2022 | 267 | 0.440 |
Why?
|
Immunoassay | 1 | 2016 | 752 | 0.430 |
Why?
|
Sequence Analysis, DNA | 9 | 2015 | 4801 | 0.420 |
Why?
|
HIV | 4 | 2018 | 1600 | 0.420 |
Why?
|
Viremia | 3 | 2022 | 735 | 0.390 |
Why?
|
Adolescent | 25 | 2023 | 85649 | 0.380 |
Why?
|
Zidovudine | 8 | 2013 | 620 | 0.360 |
Why?
|
Virus Replication | 7 | 2018 | 2531 | 0.360 |
Why?
|
Humans | 121 | 2023 | 742088 | 0.360 |
Why?
|
Amino Acid Substitution | 5 | 2013 | 1792 | 0.340 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1255 | 0.340 |
Why?
|
Adult | 60 | 2022 | 213712 | 0.330 |
Why?
|
Molecular Sequence Data | 21 | 2014 | 18112 | 0.330 |
Why?
|
Young Adult | 23 | 2020 | 56350 | 0.330 |
Why?
|
Immunoenzyme Techniques | 3 | 2013 | 1799 | 0.320 |
Why?
|
Circumcision, Male | 2 | 2020 | 150 | 0.320 |
Why?
|
Rhode Island | 3 | 2022 | 347 | 0.310 |
Why?
|
RNA-Directed DNA Polymerase | 2 | 2007 | 248 | 0.300 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2007 | 52 | 0.300 |
Why?
|
Thymidine | 1 | 2007 | 309 | 0.300 |
Why?
|
Counseling | 1 | 2015 | 1521 | 0.290 |
Why?
|
Epitopes, T-Lymphocyte | 5 | 2018 | 880 | 0.290 |
Why?
|
Infectious Disease Transmission, Vertical | 7 | 2013 | 1320 | 0.280 |
Why?
|
AIDS Serodiagnosis | 1 | 2007 | 184 | 0.280 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2020 | 4379 | 0.270 |
Why?
|
Female | 67 | 2022 | 379592 | 0.270 |
Why?
|
Male | 52 | 2022 | 349538 | 0.260 |
Why?
|
Genome, Viral | 4 | 2022 | 667 | 0.260 |
Why?
|
Genes, env | 3 | 2013 | 95 | 0.260 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 39 | 0.250 |
Why?
|
Middle Aged | 33 | 2020 | 213127 | 0.250 |
Why?
|
vif Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 53 | 0.250 |
Why?
|
Human Immunodeficiency Virus Proteins | 2 | 2016 | 65 | 0.250 |
Why?
|
Mass Screening | 4 | 2020 | 5238 | 0.240 |
Why?
|
Acquired Immunodeficiency Syndrome | 6 | 2021 | 2231 | 0.240 |
Why?
|
Polymorphism, Genetic | 6 | 2014 | 4328 | 0.240 |
Why?
|
Viral Regulatory and Accessory Proteins | 2 | 2016 | 159 | 0.240 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 4 | 2013 | 127 | 0.240 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2011 | 1820 | 0.240 |
Why?
|
Cross-Sectional Studies | 10 | 2022 | 24913 | 0.230 |
Why?
|
Consensus Sequence | 3 | 2002 | 377 | 0.230 |
Why?
|
Recombination, Genetic | 3 | 2013 | 1586 | 0.230 |
Why?
|
Base Sequence | 9 | 2014 | 12797 | 0.220 |
Why?
|
Gene Frequency | 5 | 2019 | 3587 | 0.220 |
Why?
|
Prevalence | 11 | 2022 | 15194 | 0.220 |
Why?
|
Immunodominant Epitopes | 2 | 2005 | 267 | 0.210 |
Why?
|
Computational Biology | 1 | 2015 | 3518 | 0.210 |
Why?
|
Epitopes | 4 | 2016 | 2569 | 0.210 |
Why?
|
Mutation, Missense | 2 | 2013 | 2556 | 0.200 |
Why?
|
Amino Acid Sequence | 14 | 2016 | 13814 | 0.200 |
Why?
|
Leukocytes, Mononuclear | 4 | 2022 | 1835 | 0.200 |
Why?
|
Sexual Partners | 3 | 2018 | 730 | 0.200 |
Why?
|
Selection, Genetic | 4 | 2016 | 914 | 0.190 |
Why?
|
Genes, pol | 1 | 2000 | 51 | 0.190 |
Why?
|
Incidence | 8 | 2022 | 20928 | 0.190 |
Why?
|
Molecular Typing | 2 | 2019 | 106 | 0.190 |
Why?
|
T-Lymphocytes | 5 | 2006 | 10163 | 0.190 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2023 | 3585 | 0.190 |
Why?
|
Rural Population | 4 | 2019 | 2207 | 0.180 |
Why?
|
Bayes Theorem | 3 | 2019 | 2303 | 0.180 |
Why?
|
Time Factors | 9 | 2019 | 40054 | 0.180 |
Why?
|
Infant Formula | 3 | 2012 | 199 | 0.170 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 153 | 0.170 |
Why?
|
Interferon-gamma | 3 | 2006 | 3199 | 0.170 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 39 | 0.170 |
Why?
|
Nucleosides | 1 | 2019 | 138 | 0.160 |
Why?
|
Acidosis, Lactic | 2 | 2012 | 142 | 0.160 |
Why?
|
Longitudinal Studies | 8 | 2020 | 13921 | 0.160 |
Why?
|
Host-Pathogen Interactions | 3 | 2018 | 1477 | 0.160 |
Why?
|
Gene Products, gag | 6 | 2006 | 337 | 0.160 |
Why?
|
Didanosine | 2 | 2009 | 153 | 0.160 |
Why?
|
Sequence Alignment | 4 | 2020 | 2257 | 0.160 |
Why?
|
Breast Feeding | 4 | 2012 | 1339 | 0.160 |
Why?
|
Milk, Human | 3 | 2012 | 490 | 0.150 |
Why?
|
Residence Characteristics | 2 | 2019 | 2049 | 0.150 |
Why?
|
HIV Integrase | 1 | 2018 | 120 | 0.150 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2019 | 3915 | 0.150 |
Why?
|
Receptors, CXCR4 | 2 | 2012 | 726 | 0.140 |
Why?
|
HIV Long Terminal Repeat | 5 | 2013 | 88 | 0.140 |
Why?
|
T-Lymphocyte Subsets | 2 | 2003 | 1837 | 0.140 |
Why?
|
Public Health | 4 | 2023 | 2594 | 0.140 |
Why?
|
Nucleic Acid Heteroduplexes | 1 | 1996 | 47 | 0.140 |
Why?
|
Pyridazines | 1 | 2018 | 201 | 0.140 |
Why?
|
Treatment Failure | 5 | 2022 | 2615 | 0.130 |
Why?
|
Genes, MHC Class I | 2 | 2014 | 258 | 0.130 |
Why?
|
Withholding Treatment | 1 | 2019 | 598 | 0.130 |
Why?
|
HLA Antigens | 1 | 2001 | 1382 | 0.130 |
Why?
|
Entropy | 1 | 2015 | 209 | 0.130 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2001 | 1366 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 3862 | 0.120 |
Why?
|
Gene Products, env | 4 | 2004 | 263 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 783 | 0.120 |
Why?
|
Population Density | 1 | 2014 | 194 | 0.120 |
Why?
|
HLA-B Antigens | 2 | 2018 | 353 | 0.120 |
Why?
|
Substance Abuse, Intravenous | 1 | 1998 | 522 | 0.120 |
Why?
|
Condoms | 2 | 2022 | 323 | 0.110 |
Why?
|
Awareness | 1 | 2018 | 639 | 0.110 |
Why?
|
Research Design | 2 | 2020 | 5979 | 0.110 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2013 | 2026 | 0.110 |
Why?
|
HIV Protease | 2 | 2011 | 96 | 0.110 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2015 | 323 | 0.110 |
Why?
|
rev Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 28 | 0.110 |
Why?
|
Cohort Studies | 9 | 2018 | 40450 | 0.110 |
Why?
|
Disease Progression | 4 | 2018 | 13256 | 0.110 |
Why?
|
Genetic Linkage | 2 | 2015 | 2422 | 0.110 |
Why?
|
Mastitis | 1 | 2012 | 41 | 0.110 |
Why?
|
Gene Products, nef | 3 | 2006 | 110 | 0.110 |
Why?
|
Specimen Handling | 1 | 2016 | 692 | 0.100 |
Why?
|
Codon | 1 | 2013 | 611 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1048 | 0.100 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1335 | 0.090 |
Why?
|
Suppression, Genetic | 1 | 2010 | 196 | 0.090 |
Why?
|
Africa, Southern | 2 | 2007 | 57 | 0.090 |
Why?
|
Alkynes | 2 | 2022 | 306 | 0.090 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 370 | 0.090 |
Why?
|
Adenovirus Infections, Human | 1 | 2009 | 71 | 0.090 |
Why?
|
T-Cell Antigen Receptor Specificity | 2 | 2006 | 87 | 0.080 |
Why?
|
Statistics, Nonparametric | 2 | 2013 | 2885 | 0.080 |
Why?
|
Child | 5 | 2023 | 77478 | 0.080 |
Why?
|
Cyclopropanes | 2 | 2022 | 416 | 0.080 |
Why?
|
Benzoxazines | 2 | 2022 | 301 | 0.080 |
Why?
|
Ukraine | 2 | 2019 | 111 | 0.080 |
Why?
|
Sequence Homology | 1 | 2008 | 203 | 0.080 |
Why?
|
Mycobacterium tuberculosis | 1 | 2019 | 1825 | 0.080 |
Why?
|
Geography | 3 | 2019 | 669 | 0.080 |
Why?
|
Adenoviruses, Human | 1 | 2009 | 257 | 0.080 |
Why?
|
Genetic Heterogeneity | 1 | 2011 | 732 | 0.070 |
Why?
|
Lactic Acid | 1 | 2012 | 1132 | 0.070 |
Why?
|
Gene Products, pol | 2 | 2004 | 47 | 0.070 |
Why?
|
Nelfinavir | 1 | 2006 | 68 | 0.070 |
Why?
|
Tuberculosis | 1 | 2019 | 1904 | 0.070 |
Why?
|
False Negative Reactions | 1 | 2007 | 587 | 0.070 |
Why?
|
Exons | 1 | 2012 | 2431 | 0.070 |
Why?
|
South Africa | 1 | 2011 | 1728 | 0.070 |
Why?
|
Nitriles | 2 | 2023 | 952 | 0.070 |
Why?
|
Drug Resistance | 2 | 2022 | 1608 | 0.070 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 256 | 0.070 |
Why?
|
Postpartum Period | 2 | 2009 | 1078 | 0.070 |
Why?
|
Schistosomiasis mansoni | 1 | 2006 | 85 | 0.070 |
Why?
|
Receptors, HIV | 1 | 2006 | 162 | 0.060 |
Why?
|
HLA-DQ Antigens | 1 | 2005 | 210 | 0.060 |
Why?
|
Demography | 1 | 2010 | 1650 | 0.060 |
Why?
|
Community Health Centers | 1 | 2008 | 428 | 0.060 |
Why?
|
Infant, Newborn | 5 | 2019 | 25575 | 0.060 |
Why?
|
Genome-Wide Association Study | 2 | 2021 | 12220 | 0.060 |
Why?
|
Tanzania | 3 | 2014 | 1344 | 0.060 |
Why?
|
Point Mutation | 1 | 2010 | 1624 | 0.060 |
Why?
|
Vaccines, DNA | 1 | 2006 | 305 | 0.060 |
Why?
|
Antigenic Variation | 1 | 2004 | 125 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2022 | 15494 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3151 | 0.060 |
Why?
|
HIV Protease Inhibitors | 1 | 2006 | 430 | 0.060 |
Why?
|
HLA-DR Antigens | 1 | 2005 | 644 | 0.060 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2012 | 2837 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 9941 | 0.060 |
Why?
|
Sequence Analysis, RNA | 1 | 2011 | 2011 | 0.060 |
Why?
|
Tropism | 1 | 2023 | 41 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3199 | 0.060 |
Why?
|
Biomedical Research | 1 | 2018 | 3306 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2019 | 39004 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2022 | 77098 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1849 | 0.050 |
Why?
|
Viral Tropism | 1 | 2023 | 101 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5385 | 0.050 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2021 | 9 | 0.050 |
Why?
|
Adaptor Protein Complex beta Subunits | 1 | 2021 | 13 | 0.050 |
Why?
|
Genes, rev | 1 | 2001 | 13 | 0.050 |
Why?
|
Adaptor Protein Complex 3 | 1 | 2021 | 17 | 0.050 |
Why?
|
Genes, tat | 1 | 2001 | 15 | 0.050 |
Why?
|
Genes, gag | 1 | 2001 | 61 | 0.050 |
Why?
|
Genes, nef | 1 | 2001 | 55 | 0.050 |
Why?
|
Epitope Mapping | 1 | 2002 | 311 | 0.050 |
Why?
|
District of Columbia | 1 | 2021 | 157 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14720 | 0.050 |
Why?
|
Patient Compliance | 2 | 2009 | 2680 | 0.050 |
Why?
|
Antibodies, Bispecific | 1 | 2003 | 164 | 0.050 |
Why?
|
Prospective Studies | 7 | 2023 | 53187 | 0.050 |
Why?
|
Drug Therapy, Combination | 4 | 2013 | 6483 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 1998 | 1086 | 0.050 |
Why?
|
Gene Expression Regulation | 2 | 2018 | 12071 | 0.050 |
Why?
|
Terminal Repeat Sequences | 1 | 2000 | 72 | 0.040 |
Why?
|
Amino Acids | 1 | 2005 | 1727 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5062 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2017 | 17400 | 0.040 |
Why?
|
Pyrimidines | 2 | 2023 | 2933 | 0.040 |
Why?
|
Histocompatibility Testing | 1 | 2001 | 742 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 2 | 2018 | 1871 | 0.040 |
Why?
|
New England | 1 | 2022 | 1021 | 0.040 |
Why?
|
Acute Disease | 1 | 2009 | 7141 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2003 | 1034 | 0.040 |
Why?
|
Haplotypes | 2 | 2005 | 2781 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2009 | 3164 | 0.040 |
Why?
|
Age Factors | 1 | 2015 | 18355 | 0.040 |
Why?
|
HLA-A Antigens | 1 | 2018 | 228 | 0.040 |
Why?
|
DNA Primers | 2 | 2001 | 2892 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2001 | 1368 | 0.040 |
Why?
|
Genes, Viral | 1 | 1998 | 718 | 0.040 |
Why?
|
Cloning, Molecular | 2 | 2000 | 4322 | 0.040 |
Why?
|
Pregnancy | 7 | 2013 | 29087 | 0.040 |
Why?
|
Drug Design | 1 | 2002 | 1078 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2018 | 62966 | 0.040 |
Why?
|
Social Justice | 1 | 2021 | 455 | 0.040 |
Why?
|
Simian immunodeficiency virus | 1 | 2001 | 846 | 0.030 |
Why?
|
Developing Countries | 1 | 2008 | 2789 | 0.030 |
Why?
|
Human Rights | 1 | 2018 | 302 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 165 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2022 | 1238 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2018 | 1547 | 0.030 |
Why?
|
Genetic Markers | 1 | 2001 | 2633 | 0.030 |
Why?
|
NF-kappa B | 2 | 2000 | 2500 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2018 | 1995 | 0.030 |
Why?
|
Gene Products, rev | 1 | 2012 | 31 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2000 | 1337 | 0.030 |
Why?
|
Green Fluorescent Proteins | 1 | 2018 | 2088 | 0.030 |
Why?
|
Algorithms | 5 | 2014 | 13853 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1768 | 0.030 |
Why?
|
Gene Products, tat | 2 | 2005 | 120 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2018 | 4438 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2021 | 2867 | 0.030 |
Why?
|
Lymphocyte Activation | 1 | 2003 | 5519 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 4929 | 0.030 |
Why?
|
Animals | 6 | 2010 | 168561 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1402 | 0.030 |
Why?
|
Infant | 4 | 2012 | 35070 | 0.020 |
Why?
|
Peptide Fragments | 3 | 2012 | 5095 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2008 | 5133 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 999 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 650 | 0.020 |
Why?
|
Population Surveillance | 1 | 2021 | 2616 | 0.020 |
Why?
|
Goals | 1 | 2016 | 705 | 0.020 |
Why?
|
Models, Genetic | 1 | 2001 | 3493 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 497 | 0.020 |
Why?
|
RNA | 1 | 2020 | 2747 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12344 | 0.020 |
Why?
|
Plasma | 1 | 2013 | 575 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 347 | 0.020 |
Why?
|
Europe | 2 | 2009 | 3339 | 0.020 |
Why?
|
Thailand | 1 | 2009 | 296 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 40955 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2021 | 4465 | 0.020 |
Why?
|
Cell Line | 4 | 2006 | 15994 | 0.020 |
Why?
|
Virus Internalization | 1 | 2012 | 501 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2009 | 402 | 0.020 |
Why?
|
Probability | 1 | 2014 | 2502 | 0.020 |
Why?
|
Africa | 1 | 2009 | 670 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 375 | 0.020 |
Why?
|
Alleles | 1 | 2018 | 6931 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 258 | 0.020 |
Why?
|
Communicable Disease Control | 1 | 2014 | 854 | 0.020 |
Why?
|
Virulence | 1 | 2011 | 1328 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 432 | 0.020 |
Why?
|
DNA | 1 | 2001 | 7289 | 0.020 |
Why?
|
Cameroon | 1 | 2006 | 70 | 0.020 |
Why?
|
p21-Activated Kinases | 1 | 2006 | 128 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2003 | 9274 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4187 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2009 | 654 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5692 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7770 | 0.020 |
Why?
|
Brazil | 1 | 2009 | 1263 | 0.020 |
Why?
|
Models, Biological | 1 | 2001 | 9581 | 0.020 |
Why?
|
Lamivudine | 1 | 2006 | 342 | 0.020 |
Why?
|
HLA-A3 Antigen | 1 | 2004 | 34 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 571 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2013 | 1889 | 0.010 |
Why?
|
HLA-A2 Antigen | 1 | 2004 | 213 | 0.010 |
Why?
|
Amino Acid Motifs | 1 | 2006 | 936 | 0.010 |
Why?
|
Labor, Obstetric | 1 | 2007 | 333 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2015 | 3584 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 2013 | 7721 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1997 | 5851 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 2001 | 6171 | 0.010 |
Why?
|
Infant Mortality | 1 | 2006 | 754 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8328 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2006 | 3133 | 0.010 |
Why?
|
Cross Reactions | 1 | 2002 | 841 | 0.010 |
Why?
|
Chimera | 1 | 2001 | 485 | 0.010 |
Why?
|
Computer Simulation | 1 | 2014 | 6191 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2009 | 1970 | 0.010 |
Why?
|
Zimbabwe | 1 | 2000 | 129 | 0.010 |
Why?
|
Binding Sites | 2 | 2000 | 6115 | 0.010 |
Why?
|
Regression Analysis | 1 | 2009 | 6452 | 0.010 |
Why?
|
Jurkat Cells | 1 | 2000 | 742 | 0.010 |
Why?
|
Likelihood Functions | 1 | 2002 | 1003 | 0.010 |
Why?
|
COS Cells | 1 | 2000 | 1160 | 0.010 |
Why?
|
Mexico | 1 | 2001 | 688 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2003 | 730 | 0.010 |
Why?
|
Risk Factors | 3 | 2012 | 72145 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2003 | 1866 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 1996 | 19862 | 0.010 |
Why?
|
North America | 1 | 2001 | 1249 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2006 | 6382 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23320 | 0.010 |
Why?
|
Antibody Formation | 1 | 2001 | 1402 | 0.010 |
Why?
|
Transcription Factor RelA | 1 | 1997 | 275 | 0.010 |
Why?
|
Survival Analysis | 1 | 2009 | 10248 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6534 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2006 | 6891 | 0.010 |
Why?
|
NFATC Transcription Factors | 1 | 1997 | 380 | 0.010 |
Why?
|
Gene Expression Regulation, Viral | 1 | 1997 | 442 | 0.010 |
Why?
|
Models, Molecular | 1 | 2005 | 5454 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4214 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29010 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21719 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23387 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2004 | 2524 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2001 | 2378 | 0.010 |
Why?
|
Kinetics | 1 | 2003 | 6474 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2000 | 1782 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2007 | 12017 | 0.010 |
Why?
|
Lymphocytes | 1 | 2000 | 2614 | 0.010 |
Why?
|
Transfection | 1 | 2000 | 5892 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2017 | 57683 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2004 | 9735 | 0.010 |
Why?
|
Software | 1 | 2005 | 4434 | 0.010 |
Why?
|
Logistic Models | 1 | 2006 | 13403 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2006 | 19223 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2000 | 4414 | 0.000 |
Why?
|
Mice | 2 | 2006 | 81045 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1997 | 5867 | 0.000 |
Why?
|
Macrophages | 1 | 2000 | 5655 | 0.000 |
Why?
|
Models, Statistical | 1 | 2001 | 5100 | 0.000 |
Why?
|
Glioma | 1 | 2000 | 3388 | 0.000 |
Why?
|
Aged | 1 | 2017 | 162944 | 0.000 |
Why?
|
United States | 1 | 2009 | 69693 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 1997 | 9639 | 0.000 |
Why?
|
Transcription Factors | 1 | 1997 | 12164 | 0.000 |
Why?
|